ASX:DXB Dimerix (DXB) Stock Price, News & Analysis → $5,000 Gold? (From Stansberry Research) (Ad) Free DXB Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend Yield5.16%Price TargetN/A Stock AnalysisStock Analysis Get Dimerix alerts: Email Address Ad Stansberry ResearchThe Long-Awaited End of America UpdateA 995% Gain Last Time We Shared this "Election Secret" It's a straightforward way to come out on top no matter who wins this November… It's not cryptos, or options, and anyone can do it.Click here to find out for free. About DimerixDimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs. It develops DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 for diabetic kidney disease; and DMX-700 for chronic obstructive pulmonary disease, as well as develops proprietary receptor- HIT assay technology. The company is headquartered in Fitzroy, Australia.Read More Ad Stansberry ResearchThe Long-Awaited End of America UpdateA 995% Gain Last Time We Shared this "Election Secret" It's a straightforward way to come out on top no matter who wins this November… It's not cryptos, or options, and anyone can do it.Click here to find out for free. DXB Stock News HeadlinesMay 1, 2024 | msn.comDimerix receives key paediatric investigation approval in UKApril 16, 2024 | afr.comDimerix LimitedMay 2, 2024 | Stansberry Research (Ad)Urgent dollar warningYour 2024 Election Money Blueprint Voters are angrier than ever, and it's likely to keep getting worse. The media and Wall Street keep declaring how great the economy supposedly is... but no one – besides the ultra-rich – seems to feel that way. Protect yourself with this one simple move today.April 8, 2024 | finance.yahoo.comCompanies Like Dimerix (ASX:DXB) Could Be Quite RiskyApril 8, 2024 | finance.yahoo.comInvestors ignore increasing losses at Dimerix (ASX:DXB) as stock jumps 236% this past weekApril 8, 2024 | finance.yahoo.comShareholders Will Likely Find Dimerix Limited's (ASX:DXB) CEO Compensation AcceptableApril 8, 2024 | finance.yahoo.comCalculating The Intrinsic Value Of Dimerix Limited (ASX:DXB)August 29, 2022 | finance.yahoo.comTrade Alert: Peter Meurs At Dimerix Limited (ASX:DXB), Has Just Spent AU$3.5m Buying 66% More SharesMay 2, 2024 | Stansberry Research (Ad)Urgent dollar warningYour 2024 Election Money Blueprint Voters are angrier than ever, and it's likely to keep getting worse. The media and Wall Street keep declaring how great the economy supposedly is... but no one – besides the ultra-rich – seems to feel that way. Protect yourself with this one simple move today.August 29, 2022 | finance.yahoo.comHere's Why We're Watching Dimerix's (ASX:DXB) Cash Burn SituationAugust 29, 2022 | finance.yahoo.comWe Think Dimerix (ASX:DXB) Needs To Drive Business Growth CarefullySee More Headlines Receive DXB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dimerix and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:DXB CUSIPN/A CIKN/A Webdimerix.com Phone1.212.250.8024FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,870,000.00 Net Margins-119.20% Pretax MarginN/A Return on Equity-330.96% Return on Assets-63.63% Debt Debt-to-Equity Ratio83.19 Current Ratio4.84 Quick Ratio7.91 Sales & Book Value Annual Sales$9.12 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares548,600,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta0.51 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Nina Webster B.Sc.M.B.A., M.IP.Law, MBA, Ph.D., CEO, MD & DirectorMr. Hamish George B.Com.C.A., CFO & Company SecretaryDr. David Everett Fuller BPharm (Age 60)M.D., MBBS, Chief Medical Officer Mr. Kevin Donald George Pfleger BA (Hons)MA, Ph.D., Chief Scientific AdvisorMr. Robert ShepherdChief Commercialisation OfficerKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All CompetitorsInsidersNina WebsterBought 33,000 shares on 3/27/2024Total: $10,230.00 ($0.31/share)Nina WebsterSold 93,750 sharesTotal: $11,812.50 ($0.13/share)Nina WebsterSold 2,052,956 sharesTotal: $283,307.93 ($0.14/share)Sonia PoliSold 11,334 sharesTotal: $4,533.60 ($0.40/share)Nina WebsterSold 187,500 sharesTotal: $15,000.00 ($0.08/share) This page (ASX:DXB) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressUrgent Nvidia WarningAltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmithYour bank is lying to you.MyBankTrackerThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingTrump just won 2024Porter & CompanyHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dimerix Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
